Trends in Outcomes, Financial Burden, and Mortality for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) in the United States from 2002 to 2010
暂无分享,去创建一个
A. Soubani | S. Liangpunsakul | Suthat Liangpunsakul | Ayman O Soubani | Chetna Jinjuvadia | Raxitkumar Jinjuvadia | Chaitanya Mandapakala | Navin Durairajan | Raxitkumar Jinjuvadia | N. Durairajan | Chaitanya Mandapakala | C. Jinjuvadia
[1] Anne Holland,et al. Telehealth reduces hospital admission rates in patients with COPD. , 2013, Journal of physiotherapy.
[2] D. Postma,et al. Chronic obstructive pulmonary disease. , 2002, Clinical evidence.
[3] M. Malesker,et al. Pharmacoeconomic evaluation of COPD. , 2000, Chest.
[4] Angela E. Williams,et al. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. , 2006, Primary care respiratory journal : journal of the General Practice Airways Group.
[5] T. Self,et al. The clinical and economic burden of chronic obstructive pulmonary disease in the USA , 2013, ClinicoEconomics and outcomes research : CEOR.
[6] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[7] G. Diette,et al. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. , 2003, Archives of internal medicine.
[8] R. Pauwels,et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.
[9] Cristianna A Abilez. Evaluation of Health Care Cost and Utilization Project Data (HCUP) in Healthcare Research , 2013 .
[10] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[11] G. Ogedegbe,et al. Heart failure–associated hospitalizations in the United States. , 2013, Journal of the American College of Cardiology.